Medical cannabis should not be treated as a simple answer for depression or low mood. A diagnosis can be part of the access conversation, but it does not by itself mean someone may qualify for a prescription.
For UK patients, the safer way to frame it is this: medical cannabis may be discussed in specialist assessment for some suitable patients where previous treatments have not worked well enough, caused problems, or been unsuitable. The prescriber still has to look carefully at mental-health risk, current medicines, previous treatment history, side effects, impairment, substance-use concerns and whether a cannabis-based medicinal product is appropriate at all.
This article is for patients and carers trying to understand the question before speaking to a clinician. It is not medical advice and it is not a crisis-support page. If you feel at immediate risk of harming yourself, call 999 or go to A&E. For urgent mental-health help in England, NHS advice is to use 111 online or call 111 and select the mental-health option. NHS help for suicidal thoughts also lists Samaritans on 116 123.
For broader access context, see MCPH’s guides to medical cannabis qualifying conditions and how the UK medical cannabis prescription process works.
The short answer
NHS information on medical cannabis focuses on a small number of situations where these medicines are more commonly considered, such as some severe epilepsy syndromes, chemotherapy-related nausea and vomiting, and multiple-sclerosis-related spasticity. NICE guidance on cannabis-based medicinal products does not recommend cannabis-based medicines as a routine treatment for depression.
That does not mean no private specialist will ever assess a patient with depression or low mood. It means the assessment should be careful, source-aware and honest about the evidence limits.
The useful patient question is not “does depression qualify?” It is:
- what is the diagnosis or working diagnosis?
- what previous treatments have been tried?
- what did not work, caused side effects, or was unsuitable?
- are there urgent symptoms or risk factors that need mental-health care first?
- are current medicines, alcohol, non-prescribed cannabis or other substances part of the picture?
- could THC or CBD create mood, sleep, anxiety, interaction or impairment risks?
Depression and low mood are not one thing
The NHS describes depression as more than feeling unhappy for a few days. It can affect mood, sleep, appetite, concentration, energy, work, relationships and daily life. Low mood can also appear with grief, stress, burnout, chronic pain, trauma, anxiety, ADHD, hormonal changes, substance use, physical illness or medication side effects.
That matters because a cannabis clinic should not be assessing a label in isolation. The clinician needs to know the pattern, duration, severity and risk.
Screening is especially important if there is:
- severe depression or rapidly worsening mood
- suicidal thoughts, self-harm, or feeling unsafe
- psychosis, hallucinations, paranoia or delusional beliefs
- mania, hypomania or possible bipolar disorder
- heavy alcohol use or substance-use concerns
- previous adverse reactions to cannabis
- complex medicines, sedatives or other mental-health drugs
- safeguarding concerns or unstable living circumstances
If any of these apply, the answer may be urgent support, NHS mental-health care, psychiatrist input, or stabilisation before any cannabis-based medicine is considered.
What the evidence can and cannot support
The official source line is cautious. NHS and NICE sources do not support medical cannabis as a routine depression treatment. RCPsych explains that cannabis can affect mental health and is associated with risks such as dependence and psychosis, with higher-risk patterns around stronger THC products and vulnerable people.
That does not mean every prescribed patient has the same risk. It does mean the claim must stay modest: medical cannabis is not a proven first-line or routine treatment for depression, and it should not be presented as a reliable mood treatment.
Some patients may describe changes in mood, sleep, pain, anxiety or functioning after prescribed medical cannabis. Those experiences can be real, but they are not the same as strong evidence that cannabis-based medicines treat depression. A clinician has to judge the individual situation, including whether any apparent benefit is outweighed by risk.
Previous treatment history matters
Private medical cannabis assessments usually look at whether the patient has already tried relevant conventional treatments. For depression and low mood, that may include antidepressant medicines, talking therapy, psychological support, sleep work, pain treatment, trauma-informed care, or other routes depending on the person.
MCPH usually frames the practical access question around at least two relevant treatments where applicable, but it is not a tick-box decision. The prescriber decides whether the previous treatment history is enough, whether the records support it, and whether medical cannabis is a suitable option to consider.
The Summary Care Record from the GP surgery is often the practical records document to start with. It may show current medicines, recent medicines, allergies and coded conditions. A clinic may ask for extra notes, letters or mental-health records if the SCR does not show enough detail.
That is an admin records step, not a request for a GP to approve medical cannabis.
Medicines, interactions and symptom changes
Many people researching this topic are already taking antidepressants, ADHD medicines, sleeping tablets, pain medicines, anti-anxiety medicines, antipsychotics, mood stabilisers, over-the-counter CBD, or non-prescribed cannabis. The prescriber needs the full list.
NHS medical cannabis guidance says CBD and THC can affect how other medicines work. The patient action is not to panic or self-check every combination online. It is to be complete and honest with the prescriber and pharmacist so they can assess interactions, side effects and monitoring.
Depression also changes the safety question. A medicine that causes sleepiness, dizziness, impaired concentration, anxiety, panic, hallucinations, mood changes or suicidal thoughts could be especially important for someone already struggling with mood. If symptoms worsen after starting any medicine, contact the prescribing clinician promptly. If there is immediate risk, use urgent NHS support rather than waiting for a routine clinic reply.
Do not stop, swap or add prescribed medicines without clinical advice.
What a careful assessment may include
A specialist assessment may look at:
- current symptoms and how they affect daily life
- past episodes of depression, self-harm or crisis care
- anxiety, PTSD, ADHD, bipolar disorder, psychosis or other coexisting conditions
- previous treatments and why they helped, failed, caused problems or were unsuitable
- current medicines, supplements, alcohol and non-prescribed substances
- sleep, appetite, concentration and motivation
- driving, work, caring responsibilities and impairment risk
- family history or personal history of psychosis, bipolar disorder or substance-use problems
- whether a psychiatrist or mental-health team should be involved
Patients can ask informed questions about forms such as oil, flower or extracts, and about THC, CBD, side effects and impairment. Product choice, dose, route and monitoring stay with the prescriber.
Questions to ask a clinic
Good questions are plain:
- What evidence do you rely on when assessing depression or low mood?
- Which parts of my mental-health history raise caution?
- Do my current medicines or supplements create interaction concerns?
- How do you screen for suicidality, severe depression, mania, psychosis and substance-use risk?
- What previous treatment history do you need to see?
- Is my Summary Care Record enough to start, or do you need mental-health notes?
- What would monitoring look like if a prescription were considered?
- What should I do if mood, anxiety, sleep, paranoia or suicidal thoughts worsen?
- When would you decide that medical cannabis is not suitable?
The point is not to talk someone into prescribing. It is to make the assessment safer and more honest.
What this article is not saying
This article is not saying medical cannabis treats depression. It is not saying depression automatically makes someone eligible. It is not recommending CBD, THC, flower, oil, extracts, a clinic, a pharmacy or a dose.
It is saying that depression and low mood need careful mental-health screening if medical cannabis is being discussed. The patient-led route is allowed to be practical: gather the right records, be honest about previous treatment, disclose medicines and cannabis use, and ask direct questions. The clinical decision sits with the specialist prescriber.
Sources
- NHS: Medical cannabis
- NHS: Depression in adults
- NHS: Where to get urgent help for mental health
- NHS: Help for suicidal thoughts
- NICE: Cannabis-based medicinal products, NG144
- NICE: Depression in adults: treatment and management, NG222
- NHS England: Cannabis-based products for medicinal use
- GMC: Information for doctors on cannabis-based products for medicinal use
- CQC: Cannabis-based medicinal products: what CQC expects from providers
- RCPsych: Cannabis and mental health
